Clopidogrel Monotherapy in Patients With High Bleeding Risk

  • End date
    Mar 27, 2024
  • participants needed
  • sponsor
    Mayo Clinic
Updated on 27 April 2022


The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications. Bleeding complications can cause significant problems (hospitalizations, need for blood transfusions, and even death) for patients on antiplatelet medications after coronary stents. Researchers hope to show that reducing the time on two antiplatelet agents in patients at high risk for these bleeding complications will reduce the number of bleeding events while not causing any increase in cardiovascular complications (heart attack, stent malfunction, death).

Condition Bleeding Complications
Treatment Clopidogrel, prasugrel, Tricagrelor
Clinical Study IdentifierNCT05223335
SponsorMayo Clinic
Last Modified on27 April 2022


Yes No Not Sure

Inclusion Criteria

Informed consent in adults
Successful percutaneous coronary intervention (PCI) [no non-fatal MI/stroke/repeat target revascularization/bleeding/acute kidney injury]
Academic research consortium-high bleeding risk (ARC-HBR) score ≥ 4

Exclusion Criteria

Chronic use of warfarin or direct oral anticoagulant (DOAC)
Unsuccessful PCI (see above)
Lesions with angiographic thrombus
Prior PCI within 6 months
Planned PCI or surgical intervention to treat any cardiac or noncardiac condition within 6 months
High risk lesion/stent characteristics (> 50% unprotected left main disease, bifurcation disease requiring 2 stents technique, rotational atherectomy
Vein graft
Unprotected left main intervention or history of definite stent thrombosis
Women of child-bearing age unless negative pregnancy test is done
Life expectancy < 1 year
Known drug/alcohol dependence
Assessment that the patient will not be compliant with the study protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note